Market closedADR
Nanobiotix/$NBTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Nanobiotix
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Ticker
$NBTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
110
Website
Nanobiotix Metrics
BasicAdvanced
$148M
-
-$0.80
1.40
-
Price and volume
Market cap
$148M
Beta
1.4
52-week high
$8.96
52-week low
$2.76
Average daily volume
59K
Financial strength
Current ratio
1.424
Quick ratio
1.364
Long term debt to equity
-202.819
Total debt to equity
-225.779
Interest coverage (TTM)
-2.79%
Management effectiveness
Return on assets (TTM)
-22.02%
Return on equity (TTM)
88.60%
Valuation
Price to revenue (TTM)
3.002
Price to book
-6.6
Price to tangible book (TTM)
-6.6
Price to free cash flow (TTM)
-82.207
Growth
Revenue change (TTM)
526.17%
Earnings per share change (TTM)
-53.64%
3-year revenue growth (CAGR)
167.86%
3-year earnings per share growth (CAGR)
-18.34%
What the Analysts think about Nanobiotix
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Nanobiotix stock.
Nanobiotix Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Nanobiotix Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Nanobiotix News
AllArticlesVideos
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
GlobeNewsWire·1 month ago
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
GlobeNewsWire·1 month ago
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Nanobiotix stock?
Nanobiotix (NBTX) has a market cap of $148M as of January 19, 2025.
What is the P/E ratio for Nanobiotix stock?
The price to earnings (P/E) ratio for Nanobiotix (NBTX) stock is 0 as of January 19, 2025.
Does Nanobiotix stock pay dividends?
No, Nanobiotix (NBTX) stock does not pay dividends to its shareholders as of January 19, 2025.
When is the next Nanobiotix dividend payment date?
Nanobiotix (NBTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nanobiotix?
Nanobiotix (NBTX) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.